Alpha Teknova, Inc.
TKNO Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 27, 2026
$7.11
KIRA · Stoqly’s AI analyst, in plain words
- Alpha Teknova, Inc. had $40.5M of revenue in fiscal 2025, up 7.4% on the year before. Over five years, revenue changed +5.3% a year on average.
- Its operating margin was −41.9%, up 27.4 pts: of every 100 in sales, about −42 is left after running the business.
- Alpha Teknova, Inc. lost $17.3M in fiscal 2025.
- Free cash flow was −$9.8M in fiscal 2025, −24.2% of revenue.
- Alpha Teknova, Inc. has $8.2M more cash than debt.
Market cap
$381M
P/E
—
Revenue
$40.5M
Net income
−$17.3M
Free cash flow
−$9.8M
Operating margin
−41.9%
Alpha Teknova, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+7.4%
Yes. Sales grew 7.4% last year.
Does it make a profit?
−42.6%
No. It lost money last year.
Does profit turn into cash?
−24.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Alpha Teknova, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Alpha Teknova, Inc.
- CIK
- 0001850902
Alpha Teknova, Inc. · TKNO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $36.9M | $41.4M | $36.7M | $37.7M | $40.5M |
| Revenue growth | 17.9% | 12.3% | −11.4% | 2.9% | 7.4% |
| Net interest income | −$0.6M | $0.2M | −$0.8M | −$0.7M | −$0.7M |
| Gross margin | 47.8% | 42.2% | 28.1% | 19.2% | 33.2% |
| Operating margin | −32.5% | −119.9% | −96.9% | −69.3% | −41.9% |
| Net income | −$9.8M | −$47.5M | −$36.8M | −$26.7M | −$17.3M |
| Net margin | −26.6% | −114.6% | −100.3% | −70.9% | −42.6% |
| Diluted EPS | −$0.61 | −$1.69 | −$1.16 | −$0.57 | −$0.32 |
| Cash | |||||
| Cash from operations | −$9.1M | −$27.4M | −$18.8M | −$12.4M | −$8.6M |
| Capital expenditure | $19.9M | $28.1M | $7.9M | $1.1M | $1.1M |
| Free cash flow | −$28.9M | −$55.5M | −$26.7M | −$13.5M | −$9.8M |
| FCF margin | −78.5% | −134.1% | −72.9% | −35.8% | −24.2% |
| Share count change | 323.3% | 74.6% | 13.3% | 46.9% | 14.4% |
| Debt and strength | |||||
| Cash and short-term investments | $87.5M | $42.2M | $28.5M | $30.4M | $21.3M |
| Debt incl. finance leases | $11.9M | $22.0M | $13.3M | $9.4M | $13.1M |
| Shareholders' equity | $143M | $99.9M | $90.0M | $82.4M | $68.8M |
| Current ratio | 13.1x | 5.6x | 5.1x | 3.8x | 4.6x |
| Returns and quality | |||||
| Return on capital | −14.0% | −49.3% | −37.6% | −33.6% | −22.1% |
| Return on equity | −12.3% | −39.1% | −38.7% | −31.0% | −22.8% |
| Return on tangible equity | −9.1% | −57.7% | −48.5% | −38.6% | −30.4% |
| Piotroski F-score | 2 | 2 | 4 | 4 | 5 |
| Altman Z'' | 9.5 | 0.8 | 0.1 | −0.6 | −1.6 |
Insiders bought, 12 months
$0.1M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alpha Teknova, Inc. · TKNO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.11 a share, the company is worth $381M.
Source: SEC EDGAR XBRL filings (CIK 0001850902). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.